IC-ONC: Combination Treatment Options, Biomarkers, and Immune-related Adverse Event Occurrence and Management During the COVID-19 Pandemic
Track 3: Immuno-oncology in Advanced Renal Cell Carcinoma
Post-Activity Evaluation

Exit Survey
Questions marked with a * are required
8%
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of virtual meeting
Powered by QuestionPro